TRUFF OTC
Rhelion Life Sciences Corp.
1W: -17.3%
1M: -10.9%
3M: -9.4%
YTD: +18.4%
1Y: -18.0%
3Y: -62.7%
5Y: -89.1%
$0.02
-0.00 (-7.83%)
Weekly Expected Move ±19.7%
$0
$0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$4M
-15.1% ▼
5Y CAGR: +106.8%
Gross Profit
$2M
-16.8% ▼
5Y CAGR: +141.5%
Operating Income
-$4M
+2.0% ▲
Net Income
-$6M
-51.0% ▼
EPS (Diluted)
$-0.01
-44.6% ▼
EBITDA
-$7M
-101.4% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $111K | $4M | $5M | $5M | $4M |
| YoY Growth | +0.0% | +3459.7% | +20.3% | +4.0% | -15.1% |
| Cost of Revenue | $92K | $2M | $3M | $3M | $3M |
| Gross Profit | $19K | $2M | $2M | $2M | $2M |
| Gross Margin | 17.4% | 43.2% | 42.5% | 38.7% | 37.9% |
| R&D Expenses | $15K | $306K | $51K | $25K | $18K |
| SG&A Expenses | $8M | $6M | $7M | $5M | $5M |
| Operating Expenses | $5M | $7M | $8M | $6M | $6M |
| Operating Income | -$5M | -$5M | -$6M | -$4M | -$4M |
| Operating Margin | -4142.5% | -121.5% | -135.7% | -85.2% | -98.3% |
| Interest Expense | $50K | $56K | $259K | $284K | $58K |
| Income Before Tax | -$2M | -$6M | -$8M | -$4M | -$7M |
| Tax Expense | $44K | -$160K | -$59K | -$107K | -$326K |
| Net Income | -$2M | -$5M | -$8M | -$4M | -$6M |
| Net Margin | -1482.4% | -136.7% | -160.5% | -81.8% | -145.4% |
| EPS (Diluted) | $-0.00 | $-0.01 | $-0.02 | $-0.01 | $-0.01 |
| EBITDA | -$5M | -$4M | -$7M | -$3M | -$7M |
| Shares Outstanding | 351M | 373M | 394M | 401M | 417M |